264
Participants
Start Date
December 7, 2017
Primary Completion Date
March 10, 2021
Study Completion Date
March 31, 2021
BI 409306
28 week treatment period
Placebo
28 week treatment period
NCKUH, Tainan City
New York State Psychiatric Institute, New York
Manhattan Behavioral Medicine PLLC, New York
Neurobehavioral Research, Inc., Cedarhurst
Seoul National University Bundang Hospital, Seongnam
Atlanta Center, Atlanta
Meridien Research, Maitland
Meridien Research, Orlando
MD Clinical, Hallandale
Reliable Clinical Research, Hialeah
Taoyuan Psychiatric Center, Taoyuan District
Behavioral Clinical Research, Inc., North Miami
HOP la Colombière, Montpellier
HOP Guillaume Régnier, Rennes
Hospital Universitario Marqués de Valdecilla, Santander
Precise Research Centers, Flowood
HOP Nord, Saint-Priest-en-Jarez
Michigan Clinical Research Institute PC, Ann Arbor
Alam Medical Research, Inc., Chicago
Chonnam National University Hospital, Gwangju
Arch Clinical Trials, St Louis
PsychCare Consultants Research, St Louis
St. Charles Psychiatric Associates & Midwest Research Group, Saint Charles
Lake Charles Clinical Trials LLC, Lake Charles
Clinical Trials of America, LLC, Monroe
University Hills Clinical Research, Irving
Pillar Clinical Research, LLC, Richardson
GHU Paris Psychiatrie et Neurosciences, Paris
@Health Texas, Richmond
Community Clinical Research, Inc., Austin
HOP Sainte Musse, Toulon
Alea Research, Phoenix
Altea Research Institute, Las Vegas
University of California Los Angeles, Los Angeles
Collaborative Neuroscience Network, LLC (CNS), Torrance
Behavioral Research Specialists, LLC, Glendale
Synergy East, Lemon Grove
Excell Research Inc., Oceanside
ATP Clinical Research, Inc., Costa Mesa
Collaborative Neuroscience Network, LLC (CNS), Garden Grove
Orange County Neuropsychiatric Research Center LLC, Orange
Hassman Research Institute, Berlin
University of Calgary, Calgary
Dr. Alexander McIntyre Inc., Penticton
The Medical Arts Health Research Group, Vancouver
Chatham-Kent Clinical Trials Research Centre, Chatham
Centre for Addiction and Mental Health (CAMH), Toronto
IUSMM Institut Universitaire en Sante Mentale de Montreal, Montreal
Okehazama Hospital Fujita Kokoro Care Center, Aichi, Toyoake
Fujita Health University Hospital, Aichi, Toyoake
National Center for Global Health and Medicine Kohnodai Hospital, Chiba, Ichikawa
Fukuoka University Hospital, Fukuoka, Fukuoka
Kuramitsu Hospital, Fukuoka, Fukuoka
Soushu Hospital, Kanagawa, Atsugi
Kishiro Mental Clinic, Kanagawa, Kawasaki
Nara Medical University Hospital, Nara, Kashihara
National Hospital Organization Hizen Psychiatric Medical Center, Saga, Kanzaki-gun
National Center Neurology and Psychiatry, Tokyo, Kodaira
Seoul National University Hospital, Seoul
Lead Sponsor
Boehringer Ingelheim
INDUSTRY